Hematology · Iron Deficiency AnemiaRegulatory Approvalcommercialnear-term

FDA Approves ANDA217769 for Ferric Carboxymaltose by Mylan

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Mylan7 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 6:32:25 AM

Assessment confidence: 56% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's approval of Mylan's ANDA217769 for Ferric Carboxymaltose introduces a new competitor in the iron deficiency anemia market. This could disrupt pricing and market share dynamics, necessitating a strategic response from existing players. Regulatory context from FDA (FDA AP — FERRIC CARBOXYMALTOSE (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Mylan's entry on market share and pricing strategies for iron deficiency treatments. The strongest clinical anchor is Can Vitamin D Replacement Correct Chronic Disease Anemia? In Hematology · Iron Deficiency Anemia, 5 regulatory and 5 competitive items passed relevance filtering for Mylan.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FERRIC CARBOXYMALTOSE (ORIG) (FDA). Entity match (mylan); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes for other products in this category.

Key Risks

Clinical risk from ClinicalTrials.gov (A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity) could weigh on Mylan through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)) could weigh on Mylan through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Mylan's entry may lead to increased competition, potentially affecting revenue and market positioning for current treatments in the iron deficiency anemia space.
First approval of PD‑1 inhibitors in combination with Trop-2-directed antibody-drug conjugate (ADC) in advanced TNBC, marking a potentially practice‑changing treatment option Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S.
Portfolio teams should assess the impact of Mylan's entry on market share and pricing strategies for iron deficiency treatments.

What Would Change This Assessment

This becomes more urgent if Monitor Mylan's launch strategy and market uptake of Ferric Carboxymaltose, as well as responses from competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FERRIC CARBOXYMALTOSE (ORIG)
FDAhigh relevance
Entity match (mylan); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FERRIC CARBOXYMALTOSE (ORIG)
FDAhigh relevance
Entity match (mylan); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Can Vitamin D Replacement Correct Chronic Disease Anemia?
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Assessment of Body Composition in Children Treated With Growth Hormone for the Indication of Isolated Non-acquired Growth Hormone Deficiency.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Khoury's Bone Shell Technique Versus Titanium-Reinforced Polytetrafluoroethylene for Augmentation of Horizontal Deficiency in Posterior Mandible (Histomorphometry Analysis): A Randomized Clinical Tria
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Approves Allogeneic T Cell Immunotherapy for Hematologic Malignancies
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves TREGZI for Chronic GVHD in Blood Cancer Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Drug Trials Snapshot: YARTEMLEA Approved for TA-TMA
Humanexa Signalsmedium relevance
Moderate corpus alignment

Repurposing nitazoxanide as a novel ferroptosis inducer for triple-negative breast cancer via dual disruption of iron homeostasis and the β-catenin/GPX4 axis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting lymphotoxin β receptor: from mechanism to precision therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mylan

Commercial impact

medium

Mylan's entry may lead to increased competition, potentially affecting revenue and market positioning for current treatments in the iron deficiency anemia space.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not suggest immediate regulatory changes for other products in this category.

What to watch

Monitor Mylan's launch strategy and market uptake of Ferric Carboxymaltose, as well as responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.